title: Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study.
abstract: OBJECTIVE
  Our study aimed to develop a model to predict distant recurrence in locally advanced cervical cancer, which can be used to select high-risk patients in enriched clinical trials.
  
  
  METHODS
  Our study was a retrospective analysis of a multi-institutional cohort of patients treated between 2001 and 2009. According to the order of data submission, data from three institutions were allocated to a model development cohort (n = 434), and data from the remaining two institutions were allocated to an external validation cohort (n = 115). Patient information including [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) data and clinical outcome was modeled using competing risk regression analysis to predict 5-year cumulative incidence of distant recurrence.
  
  
  RESULTS
  The competing risk analysis revealed that the following four parameters were significantly associated with distant recurrence: pelvic and para-aortic nodal positivity on FDG-PET, nonsquamous cell histology, and pretreatment serum squamous cell carcinoma antigen levels. This four-parameter model showed good discrimination and calibration, with a bootstrap-adjusted concordance index of 0.70. Also, the validation set showed good discrimination with a bootstrap-adjusted concordance index of 0.73. A user-friendly Web-based nomogram predicting 5-year probability of distant recurrence was developed.
  
  
  CONCLUSIONS
  We have developed a robust model to predict the risk of distant recurrence in patients with locally advanced cervical cancer. Further, we discussed how the selective enrichment of the patient population could facilitate clinical trials of systemic chemotherapy in locally advanced cervical cancer.
authors.affiliation: National Cancer Center, Seoul, Republic of Korea.
authors.forename: Sokbom
authors.initials: S
authors.lastname: Kang
authors.forename: Byung-Ho
authors.initials: BH
authors.lastname: Nam
authors.forename: Jeong-Yeol
authors.initials: JY
authors.lastname: Park
authors.forename: Sang-Soo
authors.initials: SS
authors.lastname: Seo
authors.forename: Sang-Young
authors.initials: SY
authors.lastname: Ryu
authors.forename: Jae Weon
authors.initials: JW
authors.lastname: Kim
authors.forename: Seung-Cheol
authors.initials: SC
authors.lastname: Kim
authors.forename: Sang-Yoon
authors.initials: SY
authors.lastname: Park
authors.forename: Joo-Hyun
authors.initials: JH
authors.lastname: Nam
mesh_terms: D000328:Adult; D000368:Aged; D059248:Chemoradiotherapy; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D008954:Models, Biological; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D049268:Positron-Emission Tomography / Q000379:methods; D056910:Republic of Korea; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000628:therapy*